SCHEMBL4892963

SCHEMBL4892963

CCCc1nn(C)c2c(=O)[nH]c(NCc3cccc(N4CCCC4)c3)nc12

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 16/20 0.48
HDAC1 Q13547 5/20 0.45
HDAC6 Q9UBN7 5/20 0.45
PDE3B Q13370 2/20 0.44
PDE3A Q14432 2/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
PDE1A P54750 1/20 0.44
PDE1B Q01064 1/20 0.44
KMT2A Q03164 1/20 0.44
PDE1C Q14123 1/20 0.44
MTOR P42345 1/20 0.43
HDAC2 Q92769 1/20 0.43
TERT O14746 1/20 0.43
PRMT6 Q96LA8 1/20 0.42
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899811 0.99 PDE5A (0.48) PDE5AHDAC1HDAC6PDE3BPDE3A
SCHEMBL4891816 0.93 PDE5A (0.46) PDE5AHDAC1HDAC6PDE3BPDE3A
SCHEMBL14021093 0.88 PDE5A (0.49) PDE5AHDAC1HDAC6PDE3BPDE3A
SCHEMBL14045340 0.87 PDE5A (0.45) PDE5AHDAC1HDAC6PDE3BPDE3A
SCHEMBL14045384 0.87 PDE5A (0.45) PDE5AHDAC1HDAC6PDE3BPDE3A
SCHEMBL14021092 0.85 PDE5A (0.46) PDE5AHDAC1HDAC6PDE3BPDE3A
SCHEMBL4898396 0.85 PDE5A (0.52) PDE5AHDAC1HDAC6PDE3BPDE3A
SCHEMBL14021111 0.84 PDE5A (0.46) PDE5AHDAC1HDAC6PDE3BPDE3A
SCHEMBL4905962 0.84 PRMT6 (0.42) PDE5AHDAC1HDAC6PDE3BPDE3A
SCHEMBL4904130 0.83 PDE5A (0.48) PDE5AHDAC1HDAC6PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242661-A1 Novel compounds useful for the treatment of degenerative & inflammatory diseases GALAPAGOS NV (BE) 2008-10-02 US claimed
US-11166956-B2 Combinations of PDE1 inhibitors and NEP inhibitors INTRA-CELLULAR THERAPIES, INC. (US) 2021-11-09 US disclosed
US-20190275046-A1 NOVEL COMBINATION INTRA-CELLULAR THERAPIES, INC. (US) 2019-09-12 US disclosed
US-10285992-B2 Combinations of PDE1 inhibitors and NEP inhibitors and associated methods INTRA-CELLULAR THERAPIES, INC. (US) 2019-05-14 US disclosed
US-20080242661-A1 Novel compounds useful for the treatment of degenerative & inflammatory diseases GALAPAGOS NV (BE) 2008-10-02 US disclosed
US-20080242661-A1 Novel compounds useful for the treatment of degenerative & inflammatory diseases GALAPAGOS NV (BE) 2008-10-02 US disclosed
WO-2008071650-A2 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10285992-B2 Combinations of PDE1 inhibitors and NEP inhibitors and associated methods PDE5A, PDE3A, PDE2A PDE5A 1/4885HDAC1 795/4885HDAC6 1585/4885
US-20080242661-A1 Novel compounds useful for the treatment of degenerative & inflammatory diseases PDE4A, PDE7B, PDE4B PDE5A 7/4885HDAC1 484/4885HDAC6 208/4885
US-20190275046-A1 NOVEL COMBINATION PDE5A, PDE2A, PDE3A PDE5A 1/4885HDAC1 1107/4885HDAC6 1763/4885
US-11166956-B2 Combinations of PDE1 inhibitors and NEP inhibitors PDE5A, ECE1, PDE3A PDE5A 1/4885HDAC1 963/4885HDAC6 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.